|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM314157441 |
| 003 |
DE-627 |
| 005 |
20250227205425.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||chi c |
| 024 |
7 |
|
|a 10.3760/cma.j.cn112140-20200505-00469
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1047.xml
|
| 035 |
|
|
|a (DE-627)NLM314157441
|
| 035 |
|
|
|a (NLM)32842382
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Wu, X
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A multicentric study on clinical characteristics and antibiotic sensitivity in children with methicillin-resistant Staphylococcus aureus infection
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.09.2020
|
| 500 |
|
|
|a Date Revised 14.09.2020
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Objective: To investigate the clinical characteristics of pediatric methicillin-resistant Staphylococcus aureus (MRSA) infection and the antibiotic sensitivity of the isolates. Methods: The clinical data of children with MRSA infection and antibiotic sensitivity of the isolates from 11 children's hospitals in Infectious Diseases Surveillance of Paediatrics (ISPED) group of China between January 1, 2018 and December 31, 2018 were collected retrospectively. The children's general condition, high-risk factors, antimicrobial therapy and prognosis, differences in clinical disease and laboratory test results between different age groups, and differences of antibiotic sensitivity between community-acquired (CA)-MRSA and hospital-acquired (HA)-MRSA were analyzed. The t test and Wilcoxon rank sum test were used for statistical analysis of the quantitative data and Chi-square test were used for comparison of rates. Results: Among the 452 patients, 264 were males and 188 were females, aged from 2 days to 17 years. There were 233 cases (51.5%) in the ≤1 year old group, 79 cases (17.5%) in the>1-3 years old group, 29 cases (6.4%) in the >3-5 years old group, 65 cases (14.4%) in the >5-10 years old group, and 46 cases (10.2%) in the>10 years old group. The main distributions of onset seasons were 55 cases (12.2%) in December, 47 cases (10.4%) in February, 46 cases (10.2%) in November, 45 cases (10.0%) in January, 40 cases (8.8%) in March. There were 335 cases (74.1%) CA-MRSA and 117 (25.9%) cases HA-MRSA. Among all cases, 174 cases (38.5%) had basic diseases or long-term use of hormone and immunosuppressive drugs. During the period of hospitalization, 209 cases (46.2%) received medical interventions. There were 182 patients (40.3%) had used antibiotics (β-lactams, glycopeptides, macrolides, carbapenems, oxazolones, sulfonamides etc) 3 months before admission. The most common clinical disease was pneumonia (203 cases), followed by skin soft-tissue infection (133 cases), sepsis (92 cases), deep tissue abscess (42 cases), osteomyelitis (40 cases), and septic arthritis (26 cases), suppurative meningitis (10 cases). The proportion of pneumonia in the ≤1 year old group was higher than the >1-3 years old group,>3-5 years old group,>5-10 years old group,>10 years old group (57.5% (134/233) vs. 30.4% (24/79), 31.0% (9/29), 38.5% (25/65), 23.9% (11/46), χ(2)=17.374, 7.293, 7.410, 17.373, all P<0.01) The proportion of skin and soft tissue infections caused by CA-MRSA infection was higher than HA-MRSA (33.4% (112/335) vs. 17.9% (21/117), χ(2)=10.010, P=0.002), and the proportion of pneumonia caused by HA-MRSA infection was higher than CA-MRSA (53.0% (62/117) vs. 42.1% (141/335), χ(2)=4.166, P=0.041). The first white blood cell count of the ≤1 year old group was higher than that children > 1 year old ((15±8)×10(9)/L vs. (13±7)×10(9)/L, t=2.697, P=0.007), while the C-reactive protein of the ≤1 year old group was lower than the 1-3 years old group,>5-10 years old group,>10 years old group (8.00 (0.04-194.00) vs.17.00 (0.50-316.00), 15.20 (0.23-312.00), 21.79(0.13-219.00) mg/L, Z=3.207, 2.044, 2.513, all P<0.05), there were no significant differences in procalcitonin (PCT) between different age groups (all P>0.05). After the treatment, 131 cases were cured, 278 cases were improved, 21 cases were not cured, 12 cases died, and 10 cases were abandoned. The 452 MRSA isolates were all sensitive to vancomycin (100.0%), linezolid (100.0%), 100.0% resistant to penicillin, highly resistant to erythromycin (85.0%, 375/441), clindamycin (67.7%, 294/434), less resistant to sulfonamides (5.9%, 23/391), levofloxacin (4.5%, 19/423), gentamicin (3.2%, 14/438), rifampicin (1.8%, 8/440), minocycline (1.1%, 1/91). The antimicrobial resistance rates were not significantly different between the CA-MRSA and HA-MRSA groups (all P>0.05). Conclusions: The infection of MRSA is mainly found in infants under 3 years old. The prevalent seasons are winter and spring, and MRSA is mainly acquired in the community. The main clinical diseases are pneumonia, skin soft-tissue infection and sepsis. No MRSA isolate is resistant to vancomycin, linezolid. MRSA isolates are generally sensitive to sulfonamides, levofloxacin, gentamicin, rifampicin, minocycline, and were highly resistant to erythromycin and clindamycin. To achieve better prognosis. clinicians should initiate anti-infective treatment for children with MRSA infection according to the clinical characteristics of patients and drug sensitivity of the isolates timely and effectively
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Characteristics
|
| 650 |
|
4 |
|a Child
|
| 650 |
|
4 |
|a Methicillin-resistant Staphylococcus aureus
|
| 650 |
|
4 |
|a Microbial sensitivity tests
|
| 650 |
|
7 |
|a Anti-Bacterial Agents
|2 NLM
|
| 650 |
|
7 |
|a Methicillin
|2 NLM
|
| 650 |
|
7 |
|a Q91FH1328A
|2 NLM
|
| 700 |
1 |
|
|a Yu, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a He, L Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, C Q
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, H M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, R Q
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jing, C M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Y H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, J K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, A W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, H L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cai, H J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Y P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wen, Z W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, J H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiao, F F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cao, Q
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, W C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hao, J H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, C H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Y Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ji, X F
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 58(2020), 8 vom: 02. Aug., Seite 628-634
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnas
|
| 773 |
1 |
8 |
|g volume:58
|g year:2020
|g number:8
|g day:02
|g month:08
|g pages:628-634
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3760/cma.j.cn112140-20200505-00469
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 58
|j 2020
|e 8
|b 02
|c 08
|h 628-634
|